Navigation Links
FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
Date:4/22/2011

SILVER SPRING, Md., April 22, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). Neisseria meningitidis is a leading cause of meningitis in young children. Even with appropriate antibiotics and intensive care, between 10 percent and 15 percent of people who develop meningococcal disease die from the infection. Another 10 percent to 20 percent suffer complications such as brain damage or loss of limb or hearing.

Although the rates of meningococcal disease are low in the United States, infants and toddlers are more susceptible to getting this serious illness. Meningococcal disease is particularly dangerous because it progresses rapidly and can cause death within hours. Early symptoms are often difficult to distinguish from influenza and other common illnesses.

"The highest rate of meningococcal disease occurs in children under one year of age. With today's approval, Menactra can now be used in children as young as 9 months of age to help prevent this potentially life-threatening disease," said Karen Midthun, M.D., director of FDA's Center for Biologics Evaluation and Research.

The safety of Menactra in children as young as 9 months was evaluated in four clinical studies in which over 3,700 participants received the vaccine. The most common adverse events reported in children who received Menactra at 9 months and 12 months of age were
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: Zogenix ... (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... AG (NYSE: NVS ). Free research on these ... On Friday, December 12, 2014, the NASDAQ Composite ended ... 1.79%, to finish the day at 17,280.83, and the S&P ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO ... Quantum Materials Corp (OTCQB:QTMM), will be speaking ... Quantum Materials (RCQM) on December 16th, 2014. The RCQM ... exotic nanomaterials in attracting top faculty and students and ... collaborate on research. "We have a ...
Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... the U.S. Department of Health and Human Services (HHS) ... flexible benefits in the exchanges, the Institute of Medicine ... some powerful special interests that benefit from costly new ... A new survey shows ...
... U.S. Food and Drug Administration and the Centers for ... review" pilot program for concurrent review of medical devices ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The FDA ... procedures for voluntary participation and guiding principles that the ...
Cached Medicine Technology:PCMA on IOM Essential Health Benefits Report: Employers and Special Interests Will Spar Over Costly Prescription Drug Mandates 2FDA, CMS Launch Pilot Program for Voluntary Parallel Review of Innovative Devices 2
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Expectant parents should leave ... Drug Administration recommends. Use of ultrasound imaging and ... not entirely risk-free, the agency warns. "Although ... due to ultrasound imaging and heartbeat monitors, prudent use ... important," Shahram Vaezy, an FDA biomedical engineer, said in ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... sleep loss is rampant in America, and work commitment is ... the No. 1 sleep killer," said Dr. Mathias Basner, an ... University of Pennsylvania Perelman School of Medicine. A time-use ... found that work is the main activity exchanged for sleep. ...
(Date:12/15/2014)... FL (PRWEB) December 15, 2014 South Florida’s ... knows that holidays can be a daze of hassle, hustle, ... and falls while decking halls, to burns when making special ... holiday hazards that can happen at any time. To prevent ... MD Now has made a list of helpful and healthful ...
(Date:12/15/2014)... -- Expert pilots process visual information more efficiently than ... decisions during landings, a new study shows. Landing ... to master, and 36 percent of all airplane crashes ... approach and landing. Researchers monitored the brain activity ... while they were at the controls of a flight ...
(Date:12/15/2014)... Los Angeles, CA (PRWEB) December 15, 2014 ... advocacy arena, the organizations AutismOne and ... who will enlighten attendees with research on the effects ... objective laboratory testing and intervention information. , Luminaries ... join additional researchers from abroad with esteemed, credentialed colleagues ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... scientific, technical and medical information products and services, ... Initial Psychotherapy Interview , has received the 2011 ... Society for the Psychological Study of Lesbian, Gay, ... a Gold Medal Life Achievement Award from the ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- The percentage ... 14 percent from 22 percent in 2008, a new survey ... the September issue of Obstetrics & Gynecology , don,t ... according to those on both sides of the abortion debate. ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- ... may help prevent life-threatening complications of chronic obstructive ... are commonly referred to as acute exacerbations, and ... Although numerous medications are available to help prevent ...
... -- Rheumatoid arthritis patients who believe in their ability ... are more likely to reach those objectives, researchers have ... achieve their physical activity goals have lower levels of ... Researchers in the Netherlands conducted an initial assessment of ...
... patients with rheumatoid arthritis (RA) who have higher levels ... achieve their physical activity goals. According to the study ... a journal of the American College of Rheumatology (ACR), ... self-reported arthritis pain and increased health-related quality of life ...
... Vanderbilt University has been awarded a $4.85 million grant ... to manage the newly established MacArthur Foundation Research Network ... on Law and Neuroscience is examining multiple effects of ... neuroscience accessible and beneficial to America,s courtrooms. The network ...
Cached Medicine News:Health News:Elsevier congratulates Dr. Charles Silverstein upon his receipt of 2 awards 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 3Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 2Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 3Health News:Achieving realistic physical activity goals benefits RA patients 2Health News:Landmark law and neuroscience network expands at Vanderbilt 2Health News:Landmark law and neuroscience network expands at Vanderbilt 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: